Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.
Hum Vaccin Immunother
; 10(10): 2942-57, 2014.
Article
em En
| MEDLINE
| ID: mdl-25483467
Palavras-chave
AE; Center for Biologics Evaluation and Research; CHMP; Committee for Medicinal Products for Human Use; MedDRA; Good Clinical Practice; CBER; Medical Dictionary for Regulatory Activities; PT; adverse event of special interest; MAE; adverse event; pIMD; confidence interval; RR; incidence rate; GCP; medically-attended adverse event; SAE; new onset chronic disease; CI; potential immune-mediated disease; AESI; preferred term; relative risk; SD; safety, potential immune-mediated disease, A(H1N1)pdm09 vaccine, H5N1 vaccine, influenza A(H5N1), pandemic influenza A(H1N1), pooled analysis; serious adverse event; NOCD; standard deviation; IR
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Polissorbatos
/
Esqualeno
/
Vacinas contra Influenza
/
Adjuvantes Imunológicos
/
Alfa-Tocoferol
/
Vírus da Influenza A Subtipo H1N1
/
Virus da Influenza A Subtipo H5N1
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Hum Vaccin Immunother
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Bélgica